# Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

> **NCT00542191** · PHASE2 · TERMINATED · sponsor: **Leo W. Jenkins Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
- **PROCEDURE:** Definitive Surgery
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT00542191
- **Lead sponsor:** Leo W. Jenkins Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2016-08-02
- **Final completion:** 2016-08-02
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Enrollment Completed
- **Last updated:** 2021-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542191, "Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00542191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*